Parvovirus B19 infection and systemic lupus erythematosus: Activation of an aberrant pathway?

European Journal of Internal Medicine

Volumn 19, Issue 5, 2008, Pages 314-318

  Aslanidis, Spyros ^a   Pyrpasopoulou, Athina ^a   Kontotasios, Kostas ^a   Doumas, Stella ^a   Zamboulis, Chryssanthos ^a  

^a Aristotle University and Hippokration General Hospital   (Greece)

Author keywords

Autoimmunity; Parvovirus B19 infection; Pathogenic mechanisms; SLE

Indexed keywords

CHROMOSOME ABERRATION; DISEASE ASSOCIATION; DNA REPAIR; ERYTHEMA INFECTIOSUM; HUMAN; LOWER RESPIRATORY TRACT INFECTION; MOLECULAR MIMICRY; PARVOVIRUS; PATHOGENICITY; REVIEW; RNA TRANSCRIPTION; SYSTEMIC LUPUS ERYTHEMATOSUS; VIRUS GENE;

AUTOANTIBODIES; DIAGNOSIS, DIFFERENTIAL; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN;

EID: 44649178714     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2007.09.013     Document Type: Review

References (49)

1. Kurien B.T., and Scofield R.H. Autoantibody determination in the diagnosis of systemic lupus erythematosus. Scand J Immunol 64 (2006) 227-235
2. Zandman-Goddard G., and Schoenfeld Y. Infections and SLE. Autoimmunity 38 (2005) 473-485
3. Severin M.C., Levy Y., and Schoenfeld Y. Systemic lupus erythematosus and parvovirus B19: causal coincidence or causative culprit?. Clin Rev Allergy Immunol 25 (2003) 41-48
4. Tan E.M., Cohen A.S., Fries J.F., Masi A.T., McShane D.J., Rothfield N.F., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25 (1982) 1271-1277
5. Cossart Y.E., Field A.M., Cant B., and Widdows D. Parvovirus-like particles in human sera. Lancet 1 (1975) 72-73
6. Heegaard E.D., and Brown K.E. Human parvovirus B19. Clin Microbiol Rev 15 (2002) 485-505
7. Allander T., Tammi M.T., Eriksson M., Bjerkner A., Tiveljung-Lindell A., and Andersson B. Cloning of a human parvovirus by molecular screening of respiratory tract samples. Proc Natl Acad Sci USA 102 (2005) 12891-12896
8. Berns K. Parvoviridae: the viruses and their replication. In: Fields B., Knipe D., Howley P., Chanock R., Melnick J., Monath T., Roizman B., and Straus S. (Eds). Fields virology (1996), Lippincott-Raven, Philadelphia, Pa 2173-2197
9. Cotmore S.F., McKie V.C., Anderson L.J., Astell C.R., and Tattersall P. Identification of the major structural and nonstructural proteins encoded by human parvovirus B19 and mapping of their genes by prokaryotic expression of isolated genomic fragments. J Virol 60 (1986) 548-557
10. Ozawa K., Ayub J., Hao Y.S., Kurtzman G., Shimada T., and Young N. Novel transcription map for the B19 (human) pathogenic parvovirus. J Virol 61 (1987) 2395-2406
11. Tsay G.J., and Zouali M. Unscrambling the role of human parvovirus B19 signaling in systemic autoimmunity. Biochem Pharmacol 72 (2006) 1453-1459
12. Christensen J., Cotmore S.F., and Tattersall P. Minute virus of mice transcriptional activator protein NS1 binds directly to the transactivation region of the viral p38 promoter in a strictly ATP-dependent manner. J Virol 69 (1995) 5422-5430
13. Christensen J., Pedersen M., Aasted B., and Alexandersen S. Purification and characterization of the major nonstructural protein (NS-1) of Aleutian mink disease parvovirus. J Virol 69 (1995) 1802-1809
14. Christensen J., Cotmare S.F., and Tattersall P. A novel cellular site-specific DNA-binding protein cooperates with the viral NS1 polypeptide to initiate parvovirus DNA replication. J Virol 71 (1997) 1405-1416
15. Solheim B.G., Rollag H., Svennevig J.L., Arafa O., Fosse E., and Bergerud U. Viral safety of solvent/detergent-treated plasma. Transfusion 40 (2000) 84-90
16. Schwarz T.F., Serke S., von Brunn A., Hottentrager B., Huhn D., Deinhardt F., et al. Heat stability of parvovirus B19: kinetics of inactivation. Zentralbl Bakteriol 277 (1992) 219-223
17. Broliden K., Tolfvenstam T., and Norbeck O. Clinical aspects of parvovirus B19 infection. J Intern Med 260 (2006) 285-304
18. Brown K.E., Anderson S.M., and Young N.S. Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science 262 (1993) 114-117
19. Brown K.E., Hibbs J.R., Gallinella G., Anderson S.M., Lehman E.D., McCarthy P., et al. Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen). N Engl J Med 330 (1994) 1192-1196
20. Rouger P., Gane P., and Salmon C. Tissue distribution of H, Lewis and P antigens as shown by a panel of 18 monoclonal antibodies. Rev Fr Transfus Immuno Hematol 30 (1987) 699-708
21. Srivastava A., Bruno E., Bridell R., Cooper R., Srivastava C., van Besien K., et al. Parvovirus B19-induced perturbation of human megakaryocytopoiesis in vitro. Blood 76 (1990) 1997-2004
22. Weigel-Kelley K.A., Yoder M.C., and Srivastava A. Recombinant human parvovirus B19 vectors: erythrocyte P antigen is necessary but not sufficient for successful transduction of human hematopoietic cells. J Virol 75 (2001) 4110-4116
23. Weigel-Kelley K.A., Yoder M.C., and Srivastava A. Alpha5beta1 integrin as a cellular coreceptor for human parvovirus B19: requirement of functional activation of beta1 integrin for viral entry. Blood 102 (2003) 3927-3933
24. Munakata Y., Saito-Ito T., Kumura-Ishii K., Huang J., Kodera T., Ishii T., et al. Ku80 autoantigen as a cellular coreceptor for human parvovirus B19 infection. Blood 106 (2005) 3449-3456
25. Parvovirus B19 (erythema infectiosum, fifth disease). Red Book 2006: Report of the Committee on Infectious Diseases. 27th ed (2006), American Academy of Pediatrics, Washington DC 484-487
26. Meyer O. Parvovirus B19 and autoimmune diseases. Jt Bone Spine 70 (2003) 6-11
27. White D.G., Woolf A.D., Mortimer P.P., Cohen B.J., Blake D.R., and Bacon P.A. Human parvovirus arthropathy. Lancet 1 (1985) 419-421
28. Reid D.M., Reid T.M., Brown T., Rennie J.A., and Eastmond C.J. Human parvovirus-associated arthritis: a clinical and laboratory description. Lancet 1 (1985) 422-425
29. Servey J.T., Reamy B.V., and Hodge J. Clinical presentations of parvovirus B19 infection. Am Fam Phys 75 (2007) 373-376
30. Woolf A.D., Campion G.V., Chishick A., Wise S., Cohen B.J., Klouda P.T., et al. Clinical manifestations of human parvovirus B19 in adults. Arch Intern Med 149 (1989) 1153-1156
31. Takahashi Y., Murai C., Shibata S., Munakata Y., Ishii T., Ishii K., et al. Human parvovirus B19 as a causative agent for rheumatoid arthritis. Proc Natl Acad Sci USA 95 (1998) 8227-8232
32. Kerr J.R., and Boyd N. Autoantibodies following parvovirus B19 infection. J Infec 32 (1996) 41-47
33. Loizou S., Cazabon J.K., Walport M.J., Tait D., and So A.K. Similarities of specificity and cofactor dependence in serum antiphospholipid antibodies from patients with human parvovirus B19 infection and from those with systemic lupus erythematosus. Arthritis Rheum 40 (1997) 103-108
34. Uthman I.W., and Gharavi A.E. Viral infections and antiphospholipid antibodies. Semin Arthritis Rheum 31 (2002) 256-263
35. Seve P., Ferry T., Koenig M., Cathebras P., Rousset H., and Broussolle C. Lupus-like presentation of parvovirus B19 infection. Semin Arthritis Rheum 34 (2005) 642-648
36. Ideguchi H., Ohno S., and Ishigatsubo Y. A case of pure red cell aplasia and systemic lupus erythematosus caused by human parvovirus B19 infection. Rheumatol Int 27 (2007) 411-414
37. Caliskan R., Masatlioglu S., Aslan M., Altun S., Saribas S., Ergin S., et al. The relationship between arthritis and human parvovirus B19 infection. Rheumatol Int 26 (2005) 7-11
38. Pugliese A, Beltramo T, Torre D, Roccatello D. Parvovirus B19 and immune disorders. Cell Biochem Funct 2006 [epub Aug. 18].
39. Nesher G., Osborn T., and Moore T.L. Parvovirus infection mimicking systemic lupus erythematosus. Semin Arthritis Rheum 24 (1995) 297-303
40. In: Zouali M. (Ed). Molecular autoimmunity (2005), Springer Science/Business Media, Inc., New York 437
41. Fujinami R.S., von Herrath M.G., Christen U., and Whitton J.L. Molecular mimicry, bystander activation or viral persistence: infections and autoimmune disease. Clin Microbiol Rev 19 (2006) 80-94
42. Albert L.J., and Inman R.D. Molecular mimicry and autoimmunity. N Engl J Med 341 (1999) 2068-2074
43. Lunardi C., Tiso M., Borgato L., Nanni L., Millo R., De Sandre G., et al. Chronic parvovirus B19 infection induces the production of anti-virus antibodies with autoantigen binding properties. Eur J Immunol 28 (1998) 936-948
44. Gasser S., and Raulet D. The DNA damage response, immunity and cancer. Semin Cancer Biol 16 (2006) 344-347
45. Emlen W., Niebur J., and Kadera R. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol 152 (1994) 3685-3692
46. Quinn J.P., Simpson J., and Farina A.R. The Ku complex is modulated in response to viral infection and other cellular changes. Biochim Biophys Acta 1131 (1992) 181-187
47. Mimori T., and Hardin J.A. Mechanism of interaction between Ku protein and DNA. J Biol Chem 261 (1986) 10375-10379
48. Reeves WH. Antibodies to the p70/p80 (Ku) antigens in systemic lupus erythematosus. Rheum Dis Clin North Am 18 (1992) 391-414
49. Reeves W.H., Satoh M., Wang J., Chou C.H., and Ajmani A.K. Systemic lupus erythematosus. Antibodies to DNA, DNA-binding proteins, and histones. Rheum Dis Clin North Am 20 (1994) 1-28